Hansoh Pharmaceutical Group Company Limited: all 186 studies

Page 2 of 2. Open to participants first (116), then studies with results posted, then the rest; newest registration first within each.

• A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy SubjectsRecruitingNCT05942625Phase 1
• A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid TumorsNot yet recruitingNCT05940116Phase 1
• A Study of HS-10353 in Adult Participants With Major Depressive DisorderNot yet recruitingNCT05938179Phase 2
• A Phase II Study of HS-10353 in Participants With Postpartum DepressionNot yet recruitingNCT05937867Phase 2
• A Phase I Study of HS-10386 in Participants With Advanced Solid TumorsRecruitingNCT05911464Phase 1
• ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other SarcomasRecruitingNCT05830123Phase 2
• A Study of Hansoh (HS)-10502 in Patients With Advanced Solid TumorsRecruitingNCT05740956Phase 1
• A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast CancerRecruitingNCT05504213Phase 1
• Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung CancerRecruitingNCT05435274Phase 1/2
• Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)RecruitingNCT05435248Phase 1/2
• A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseNot yet recruitingNCT05367765Phase 4
• A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.RecruitingNCT05367700Phase 1
• A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.RecruitingNCT05353205Phase 4
• A Study of HS-20089 in Patients With Advanced Solid TumorsRecruitingNCT05263479Phase 1
• Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid TumorsRecruitingNCT05207787Phase 1/2
• A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung CancerRecruitingNCT04951635Phase 3
• A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in PatientsStatus unknownNCT03849768Phase 3Results posted
• A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLCStatus unknownNCT02981108Phase 1/2Results posted
• A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults With Acute SchizophreniaCompletedNCT07550387Phase 2
• A Drug-Drug Interaction Study Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets(Yasmin®)CompletedNCT07181343Phase 1
• Evaluating the Efficacy and Safety of Intra-articular Injection of HS-20116 in Patients With Knee OsteoarthritisCompletedNCT07047196Phase 3
• Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment FailureCompletedNCT06935409Phase 3
• A Study of HS-20094 in Patients With T2DMCompletedNCT06901648Phase 2
• A Study of HS-20094 in Chinese Adults With Overweight or ObesityCompletedNCT06839664Phase 3
• Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHBActive, not recruitingNCT06743438Phase 4
• ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung CancerCompletedNCT06498479Phase 3
• A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese SubjectsCompletedNCT06118021Phase 2
• A Study of HS-20094 in T2DM ParticipantsCompletedNCT06118008Phase 2
• A Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of HS-10383Status unknownNCT06092983Phase 1
• ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung CancerWithdrawnNCT06052423Phase 2
• A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy SubjectsCompletedNCT06033742Phase 1
• Study of HS-10517 in Chinese Adult ParticipantsStatus unknownNCT05779579Phase 1/2
• Comparing of the PK, PD, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy AdultsStatus unknownNCT05777109Phase 1
• A Study of HS-10380 in Chinese ParticipantsStatus unknownNCT05480592Phase 1
• Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLCStatus unknownNCT05430386Phase 1
• First-in-Human Study to Investigate the Safety and Tolerability and Pharmacokinetics of HS-10383Status unknownNCT05429723Phase 1
• A PhaseⅠStudy of HS-10381 in Patients With Advanced Solid TumorsStatus unknownNCT05378178Phase 1
• Phase 1/2 Study of HS-10370 in Patients with Advanced Solid TumorsStatus unknownNCT05367778Phase 1/2
• ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid TumorsStatus unknownNCT05276609Phase 1
• A Study To Evaluate The Safety, Tolerability And Pharmacokinetics of HS-10345 In Treatment-Resistant DepressionCompletedNCT05196971Phase 1
• A Study of HS-10353 in Chinese Participants.CompletedNCT05195203Phase 1
• A Study of HS-20094 in Healthy ParticipantsStatus unknownNCT05116410Phase 1
• A Study of HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast CancerStatus unknownNCT05044988Phase 2
• Phase I Study to Evaluate Safety, Tolerability, and Pharmacokinetics of HS-10360 in Healthy Subjects.Status unknownNCT04986436Phase 1
• A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR MutationStatus unknownNCT04951648Phase 3
• Comparing of the Pharmacokinetic, Safety and Immunogenicity of HS-20090-2 Injection and Prolia® in Healthy AdultsStatus unknownNCT04940845Phase 1
• Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR MutationsActive, not recruitingNCT04923906Phase 3
• Bioequivalence of Dapagliflozin 10 mg Tablets Under Fed ConditionsCompletedNCT04881006Phase 1
• Bioequivalence of Dapagliflozin 10 mg Tablets Under Fasting ConditionsCompletedNCT04880993Phase 1
• Evaluation of Clinical Equivalence Between Two Linaclotide Products in the Treatment of Chronic Idiopathic ConstipationStatus unknownNCT04804267Phase 3
• Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive MutationsActive, not recruitingNCT04687241Phase 3
• Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Administration of HS-10356 in Healthy VolunteersStatus unknownNCT04652297Phase 1
• Phase I Study of the HS-10352 in Patients With Advanced Breast CancerStatus unknownNCT04631835Phase 1
• Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy AdultsStatus unknownNCT04494373Phase 1
• Evaluation of Drug Interaction Between HS-10234 and EmtriccitabineCompletedNCT04477096Phase 1
• PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid TumorsStatus unknownNCT04477057Phase 1
• A Study of HS-10342 in Patients With Advanced Solid TumorCompletedNCT04060511Phase 1
• Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With NDD-CKDStatus unknownNCT03903809Phase 3
• Study of the Efficacy and Safety of HS-10234 in Patients With Chronic Hepatitis B Virus InfectionCompletedNCT03903796Phase 3
• Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With Chronic Kidney Disease on DialysisCompletedNCT03902691Phase 3
• A Trial to Assess the Efficacy and Safety of Morinidazole in Women With Pelvic Inflammatory DiseaseStatus unknownNCT03391440Phase 4
• A Trial to Assess the Efficacy and Safety of Morinidazole in Patients With AppendicitisStatus unknownNCT03380793Phase 4
• Tolerability, Safety, Pharmacokinetics and Efficacy of HS-10241 Single Agent or Combined With Apatinib in Patients With Advanced Solid TumorsStatus unknownNCT03243643Phase 1
• A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid TumoursStatus unknownNCT02977364Phase 1
• Tolerability to HS-20004 With Titration Administration in Type 2 Diabetic PatientsStatus unknownNCT02750007Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple s.c Doses HS-20004 in Healthy Chinese VolunteersCompletedNCT02746315Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HS-20004 in Healthy Chinese VolunteersCompletedNCT02746302Phase 1
• Safety & Pharmacokinetics of Pegolsihematide for Treatment of Anemia Patient With Myelodysplastic SyndromesStatus unknownNCT02619097Phase 1
• Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on DialysisStatus unknownNCT02586402Phase 2
• A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP PatientsStatus unknownNCT02511340Phase 2
• Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With MetforminStatus unknownNCT02477969Phase 3
• Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 PatientsStatus unknownNCT02477865Phase 3
• Evaluate the Pharmacokinetics of Digoxin When Coadministered With PEX168 in Healthy Adult SubjectsCompletedNCT02472236Phase 1
• Polyethylene Glycol Loxenatide Pharmacokinetics Study in Subjects With Normal and Insufficiency Renal FunctionStatus unknownNCT02467790Phase 1
• Evaluate the Pharmacokinetics of Warfarin When Coadministered With PEX168 in Healthy Adult SubjectsCompletedNCT02461914Phase 1
• Evaluate the Pharmacokinetics of Simvastatin When Coadministered With PEX168 in Healthy Adult SubjectsCompletedNCT02447601Phase 1
• Safety & Efficacy of EPO-018B for the Treatment of Anemia in Participants With Chronic Kidney Diseases Not on DialysisStatus unknownNCT02403362Phase 2
• Safety & Efficacy of EPO-018B for the Treatment of Anemia in Participants With ERSD Receiving Maintenance HemodialysisStatus unknownNCT02366325Phase 2
• Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis BStatus unknownNCT02366247Phase 3
• Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis BCompletedNCT02366208Phase 2
• Phase I Trial to Investigate Cafusertib Hydrochloride Monotherapy in Chinese Patients With Advanced Solid TumoursStatus unknownNCT02314884Phase 1
• The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CMLCompletedNCT02204644Phase 3
• Phase I Trial to Investigate Cafusertib Hydrochloride in Combination With Low Dose Cytarabine in Chinese Patients With Acute Myeloid Leukaemia (AML)Status unknownNCT02140606Phase 1
• A Phase Ⅰa Study of Azilsartan Trimethylethanolamine in Healthy VolunteersStatus unknownNCT01985152Phase 1
• A Study of Sustained-Release Desvenlafaxine Hydrochloride for the Treatment of Major Depressive DisorderStatus unknownNCT01977378Phase 2/3
• Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat SchizophreniaCompletedNCT01623713Phase 2

← Hansoh Pharmaceutical Group Company Limited overview and focus areas